Study guide

31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria)

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria)

Key Takeaways Explain This Topic AI

In a positively skewed distribution the mean is greater than the median, which is greater than the mode, so the median and interquartile range describe the data best.

A 95% confidence interval that excludes the null value (0 for a difference, 1 for a ratio) corresponds to a statistically significant result at p below 0.05.

Sensitivity is TP divided by (TP plus FN), specificity is TN divided by (TN plus FP); a highly sensitive negative test rules out (SnNOut) and a highly specific positive test rules in (SpPIn).

As prevalence falls, the positive predictive value falls while sensitivity and specificity stay the same.

Serial testing (positive on both tests) raises specificity, while parallel testing (positive on either test) raises sensitivity.

Last updated: October 2026

Why this area matters

The TOS asks you to compute rates and ratios and apply biostatistics to research findings. Screening programs such as newborn screening, cervical screening, TB case-finding and NCD risk screening depend on understanding test performance. Many board items are short calculations from a 2x2 table, or a choice of the correct statistical test.

Data Types and Probability Distributions

Selecting appropriate statistical methods requires precise identification of variable types and underlying distribution shapes.

Scales of Measurement

Qualitative (Categorical):

Nominal: Unordered categories without intrinsic mathematical hierarchy (e.g., biological sex, ABO blood type, mortality status [alive/dead]).

Ordinal: Ordered categorical ranks with non-standardized or unequal intervals between steps (e.g., cancer staging I-IV, Glasgow Coma Scale, NYHA heart failure classes, Likert pain scales).

Quantitative (Numerical):

Discrete: Integer counts that cannot take fractional values (e.g., number of clinic visits, lifetime pregnancies, discrete seizure episodes).

Continuous: Real numbers along an unbroken continuum with meaningful decimal fractions (e.g., serum creatinine, blood pressure, core body temperature).

The Gaussian (Normal) Distribution

The normal distribution is a symmetrical, unimodal, bell-shaped distribution where the three measures of central tendency coincide exactly:

  • Mean = Median = Mode \text{Mean} = \text{Median} = \text{Mode} Mean = Median = Mode
  • The Empirical Rule (68-95-99.7 Rule)

In a perfectly Gaussian distribution governed by mean ( μ \mu μ ) and standard deviation ( σ \sigma σ ):

μ ± 1 σ \mu \pm 1\sigma μ ± 1 σ contains 68.27 % 68.27\% 68.27% of all observations.

μ ± 1.96 σ \mu \pm 1.96\sigma μ ± 1.96 σ contains exactly 95.00 % 95.00\% 95.00% of observations (often approximated as μ ± 2 σ \mu \pm 2\sigma μ ± 2 σ containing 95.45 % 95.45\% 95.45% ).

μ ± 3 σ \mu \pm 3\sigma μ ± 3 σ contains 99.73 % 99.73\% 99.73% of all observations.

Skewed Distributions and Measures of Central Tendency

When data violate normality, extreme outliers pull distribution parameters unevenly:

Positively Skewed (Right-Skewed):

The distribution has a prolonged tail extending to the positive (right) side.

Outliers pull the mean upward: Mode < Median < Mean \text{Mode} < \text{Median} < \text{Mean} Mode < Median < Mean .

Preferred summary metrics: Median and Interquartile Range (IQR = Q3 - Q1) , which are resistant to extreme outliers.

Clinical examples: Length of hospital stay, ICU ventilation hours, serum viral loads, annual healthcare expenditures.

Negatively Skewed (Left-Skewed):

The distribution has a prolonged tail extending to the negative (left) side.

Outliers pull the mean downward: Mean < Median < Mode \text{Mean} < \text{Median} < \text{Mode} Mean < Median < Mode .

Clinical example: Age at death from natural causes in developed nations.

Measures of dispersion, standard error and confidence intervals

Range: maximum minus minimum.

Interquartile range: the 25th to 75th percentile, used with the median for skewed data.

Variance and standard deviation (SD): spread around the mean, used for normally distributed data.

Coefficient of variation: SD divided by the mean, used to compare variability across different scales.

Standard error of the mean: SD divided by the square root of n. It measures the precision of the sample mean and shrinks as the sample grows.

The 95% confidence interval is about the estimate plus or minus 1.96 standard errors. It is the range that would contain the true population value in 95% of repeated samples.

Narrow intervals mean precise estimates.

If the 95% CI of a difference includes 0, or the CI of a ratio (RR, OR) includes 1, the result is not statistically significant at the 0.05 level.

Statistical significance is not clinical importance. A tiny effect can be significant in a huge sample, so look at the effect size and the CI.

Hypothesis Testing, Decision Errors & Statistical Power

Hypothesis testing evaluates whether empirical data provide sufficient evidence to reject a baseline assertion.

Null Hypothesis ( H 0 H_0 H 0 ​ ): States that there is no true difference between study groups or no association between exposure and outcome ( H 0 : μ 1 = μ 2 H_0: \mu_1 = \mu_2 H 0 ​ : μ 1 ​ = μ 2 ​ ).

Alternative Hypothesis ( H a H_a H a ​ or H 1 H_1 H 1 ​ ): States that a true difference or association exists ( H a : μ 1 ≠ μ 2 H_a: \mu_1 \ne \mu_2 H a ​ : μ 1 ​  = μ 2 ​ ).

The Error Matrix in Hypothesis Testing

Reality in Nature Accept Null Hypothesis ( H 0 H_0 H 0 ​ Not Rejected) Reject Null Hypothesis ( H 0 H_0 H 0 ​ Rejected)

Null Hypothesis is TRUE (No difference) Correct Decision: True Negative ( 1 − α 1 - \alpha 1 − α ) Type I Error ( α \alpha α ) : False Positive

Null Hypothesis is FALSE (True difference) Type II Error ( β \beta β ) : False Negative Correct Decision: Statistical Power ( 1 − β 1 - \beta 1 − β )

Type I Error ( α \alpha α ): Rejecting the null hypothesis when it is genuinely true (finding a difference that does not exist). The significance threshold is conventionally set at α = 0.05 \alpha = 0.05 α = 0.05 (5%). The p p p -value represents the exact probability of obtaining a test statistic as extreme as or more extreme than observed, assuming H 0 H_0 H 0 ​ is true. If p < α p < \alpha p < α , H 0 H_0 H 0 ​ is rejected.

Type II Error ( β \beta β ): Failing to reject the null hypothesis when it is genuinely false (failing to detect a real difference). Conventionally set at β = 0.20 \beta = 0.20 β = 0.20 (20%).

Statistical Power ( 1 − β 1 - \beta 1 − β ): The probability of correctly rejecting a false null hypothesis (detecting a true treatment difference). The acceptable standard is ≥ 80 % \ge 80\% ≥ 80% ( 0.80 0.80 0.80 ).

Determinants of Statistical Power

Statistical power is mathematically increased by:

Increasing sample size ( N N N ): Enlarges denominator degrees of freedom and narrows standard error.

Increasing effect size: A large difference between treatment arms is easier to detect than a subtle one.

Decreasing measurement variance / standard deviation ( σ \sigma σ ): Minimizes background biological noise.

Increasing the alpha threshold ( α \alpha α ): Moving α \alpha α from 0.01 to 0.05 increases power, but raises the risk of Type I errors.

Inferential Statistical Test Selection Grid

Choosing the correct bivariate statistical test depends on the scale of measurement, data distribution, and group independence:

Dependent Variable Scale Distribution Assumption Study Design / Number of Comparison Groups Correct Statistical Test

  • Continuous Normal (Parametric) 2 independent groups Two-sample Independent Student's t-test
  • Continuous Normal (Parametric) 2 paired / matched groups (pre- vs. post-test) Paired Student's t-test
  • Continuous Normal (Parametric) ≥ 3 \ge 3 ≥ 3 independent groups One-way Analysis of Variance (ANOVA)
  • Continuous / Ordinal Skewed (Non-parametric) 2 independent groups Mann-Whitney U Test (Wilcoxon Rank-Sum)
  • Continuous / Ordinal Skewed (Non-parametric) 2 paired / matched groups Wilcoxon Signed-Rank Test
  • Continuous / Ordinal Skewed (Non-parametric) ≥ 3 \ge 3 ≥ 3 independent groups Kruskal-Wallis Test

Categorical / Proportions Expected counts ≥ 5 \ge 5 ≥ 5 in all cells 2 or more independent groups (contingency table) Chi-Square ( χ 2 \chi^2 χ 2 ) Test of Independence

Categorical / Proportions Expected count < 5 < 5 < 5 in any cell 2x2 table with small sample size Fisher's Exact Test

  • Categorical / Proportions Paired binary data 2 paired groups (e.g., discordant pairs pre/post) McNemar Test
  • Correlation and Regression

Pearson Correlation Coefficient ( r r r ): Quantifies the linear association between two continuous, normally distributed variables. Ranges from − 1.0 -1.0 − 1.0 (perfect inverse linear correlation) to + 1.0 +1.0 + 1.0 (perfect direct linear correlation), with 0.0 0.0 0.0 indicating no linear correlation.

Spearman Rank Correlation ( ρ \rho ρ ): Non-parametric equivalent of Pearson correlation, evaluating monotonic relationships between non-normally distributed or ordinal variables.

Coefficient of Determination ( R 2 R^2 R 2 ): Calculated as r 2 r^2 r 2 ; represents the proportion of total variance in the dependent variable explained by the independent variable.

Linear vs. Logistic Regression: Linear regression models continuous outcome variables ( y = β 0 + β 1 x y = \beta_0 + \beta_1 x y = β 0 ​ + β 1 ​ x ). In contrast, Logistic Regression models dichotomous binary outcomes (e.g., survival vs. death; cured vs. relapsed) and generates Adjusted Odds Ratios controlling for multiple clinical confounders.

Screening Test Validity, Predictive Values & Likelihood Ratios

Screening identifies unrecognized disease in asymptomatic individuals to allow early therapeutic intervention.

Validity Metrics: Sensitivity and Specificity

Diagnostic Test Result True Disease Positive ( D + D+ D + ) True Disease Negative ( D − D- D − ) Predictive Value Formula

Test Positive ( T + T+ T + ) a a a (True Positive, TP) b b b (False Positive, FP) PPV = a a + b \text{PPV} = \frac{a}{a + b} PPV = a + b a ​

Test Negative ( T − T- T − ) c c c (False Negative, FN) d d d (True Negative, TN) NPV = d c + d \text{NPV} = \frac{d}{c + d} NPV = c + d d ​

Test Validity Metric Sensitivity = a a + c \text{Sensitivity} = \frac{a}{a + c} Sensitivity = a + c a ​ Specificity = d b + d \text{Specificity} = \frac{d}{b + d} Specificity = b + d d ​ Accuracy = a + d a + b + c + d \text{Accuracy} = \frac{a + d}{a + b + c + d} Accuracy = a + b + c + d a + d ​

Sensitivity (True Positive Rate): The probability that a diseased individual tests positive: T P T P + F N \frac{TP}{TP + FN} TP + FN TP ​ .

Mnemonic: SnNOut: A test with high S e n sitivity, when N egative, rules Out the disease.

Clinical application: Initial public health screening where missing a case carries catastrophic consequences (e.g., ELISA screening for HIV; rapid molecular testing for presumptive tuberculosis; neonatal metabolic screening under RA 9288).

Specificity (True Negative Rate): The probability that a non-diseased individual tests negative: T N T N + F P \frac{TN}{TN + FP} TN + FP TN ​ .

Mnemonic: SpPIn: A test with high Sp ecificity, when P ositive, rules In the disease.

Clinical application: Confirmatory diagnostic verification before initiating toxic, invasive, or stigmatizing therapies (e.g., the confirmatory rapid HIV diagnostic algorithm, which replaced the Western blot in the Philippines; histopathological biopsy for malignancy).

Predictive Values and the Impact of Population Prevalence

Positive Predictive Value (PPV): The probability that an individual with a positive test result genuinely possesses the disease: a a + b \frac{a}{a + b} a + b a ​ .

Negative Predictive Value (NPV): The probability that an individual with a negative test result is genuinely free of the disease: d c + d \frac{d}{c + d} c + d d ​ .

Cardinal Epidemiologic Principle: Prevalence Dependence

Sensitivity and Specificity are intrinsic characteristics of the test methodology itself; they do not change when the test is applied to populations with differing disease prevalence.

PPV and NPV are fundamentally dependent on disease prevalence:

As population prevalence increases : PPV increases markedly , while NPV decreases slightly.

As population prevalence decreases : PPV plummets (meaning the vast majority of positive tests represent false positives), while NPV approaches 100% .

Likelihood Ratios (LR)

Likelihood ratios quantify the clinical diagnostic power of a test result independently of disease prevalence:

Positive Likelihood Ratio (LR+): The ratio of the probability of a positive test in a diseased individual compared to a non-diseased individual:

L R + = Sensitivity 1 − Specificity = True Positive Rate False Positive Rate LR+ = \frac{\text{Sensitivity}}{1 - \text{Specificity}} = \frac{\text{True Positive Rate}}{\text{False Positive Rate}} L R + = 1 − Specificity Sensitivity ​ = False Positive Rate True Positive Rate ​

Negative Likelihood Ratio (LR-): The ratio of the probability of a negative test in a diseased individual compared to a non-diseased individual:

L R − = 1 − Sensitivity Specificity = False Negative Rate True Negative Rate LR- = \frac{1 - \text{Sensitivity}}{\text{Specificity}} = \frac{\text{False Negative Rate}}{\text{True Negative Rate}} L R − = Specificity 1 − Sensitivity ​ = True Negative Rate False Negative Rate ​

Clinical Utility Thresholds:

L R + > 10 LR+ > 10 L R + > 10 : Substantially increases disease probability; excellent for ruling in disease.

L R − < 0.1 LR- < 0.1 L R − < 0.1 : Substantially decreases disease probability; excellent for ruling out disease.

L R = 1.0 LR = 1.0 L R = 1.0 : Completely uninformative; post-test probability equals pre-test probability.

Mathematical translation: Post-test Odds = Pre-test Odds × L R \text{Post-test Odds} = \text{Pre-test Odds} \times LR Post-test Odds = Pre-test Odds × L R .

Screening Biases: Methodological Pitfalls

Apparent survival improvements attributed to screening initiatives are frequently artifacts of methodological bias:

Lead-Time Bias: Occurs when screening identifies disease earlier in its subclinical phase without altering the natural history or final time of death. The chronological duration between diagnosis and death appears prolonged, creating the false illusion of therapeutic efficacy.

Length-Time Bias (Prognostic Selection Bias): Screening tests preferentially detect indolent, slowly progressive disease variants because their asymptomatic preclinical phase is prolonged. Aggressive, rapidly fatal malignancies have brief preclinical phases and emerge between screening rounds (interval cancers). Consequently, screened cohorts demonstrate spuriously superior survival rates.

Overdiagnosis Bias: The detection and treatment of indolent pseudodisease—abnormalities meeting microscopic or radiographic criteria for disease that would never have produced symptoms or shortened life expectancy during the patient's natural lifespan (e.g., low-grade prostate carcinoma, thyroid microcarcinomas).

Volunteer Bias (Self-Selection Bias): Individuals who voluntarily participate in screening programs typically possess higher health literacy, healthier lifestyle behaviors, and greater therapeutic adherence than non-participants, confounding outcome comparisons.

More on screening tests and programs

ROC curve: a plot of sensitivity against 1 minus specificity across cut-offs. The area under the curve measures overall accuracy (1.0 is perfect and 0.5 is useless).

Lowering the cut-off for positivity raises sensitivity and lowers specificity, as with a lower fasting glucose threshold.

Combining tests:

Serial (sequential) testing: positive only if both tests are positive. It increases specificity and is used to confirm diagnoses, as in the HIV testing algorithm.

Parallel testing: positive if either test is positive. It increases sensitivity and is used when missing a case is dangerous.

Reliability (precision) is the consistency of repeated results, between observers (kappa statistic) or within one observer. Validity is closeness to the truth. A test can be reliable but not valid.

Wilson-Jungner criteria for a screening program:

  • the condition is an important health problem ;
  • it has a recognizable latent or early stage ;
  • an acceptable, accurate test exists;
  • effective treatment for early disease is available;
  • facilities for diagnosis and treatment exist;
  • the policy on whom to treat is agreed;
  • the cost is balanced against overall spending;

case-finding is continuous.

Examples in the Philippines: newborn screening, VIA or HPV cervical screening, BP and glucose screening under PhilPEN, and TB screening of contacts and high-risk groups.

Loading diagram... Decision Tree for Selecting Bivariate Inferential Statistical Tests